On Thursday, research acceleration specialist Intermolecular, Inc (IMI) reported its Q2 2013 earnings results. The company reported total revenues of $16.6 million, with $12.8 million derived from ongoing collaborative development programs (CDP) and $3.8 million derived from licensing and royalty revenue. Intermolecular also reported a net loss of $744,000 or $0.02/share on a GAAP basis. These statistics combined, the company was roughly in line with analyst estimates which set the expectation for $16.54 million in revenues and a loss of $0.01/share.
Intermolecular now trades with a market capitalization of $290 million according to the intraday price of $6.50 as of July 26, 2013. As of June 30, the company carried a cash balance of roughly $80 million and...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|